Viva Biotech Holdings (VBIZF) Comparison with companies in other sectors?

Viva Biotech Holdings has a share price of 2.08B. You can analyze Viva Biotech Holdings (VBIZF) competitors across different market sectors through stock heatmaps.

What are VBIZF's NET and operating margins?

Viva Biotech Holdings (VBIZF) operating margin is around 0.09, and net profit margin is approximately -0.00 as of the latest reports.

In what way does VBIZF's earnings per share (EPS) trend reflect its financial momentum?

Viva Biotech Holdings (VBIZF) EPS is 0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Viva Biotech Holdings is 18.90, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Viva Biotech Holdings?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Viva Biotech Holdings like P/E which is -9951.74, P/B which is 0.83, and PEG which is -13.88. Compare them with sector averages to evaluate if the stock is priced fairly.

Viva Biotech Holdings

VBIZF•PNK

Healthcare

Biotechnology

$0.19

$0.00(0.00%)

Fundamental Analysis of Viva Biotech Holdings (VBIZF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.01

P/E Ratio

18.90

ROE

-0.00%

Net Margin

-0.00%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$393.16M

Shares OutstandingTotal number of shares issued

$2.08B

Book Value/ShareNet worth per share

$1.63

Revenue/ShareAnnual revenue per share

$0.85

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.01

Net MarginNet income as percentage of revenue

-0.02%

Operating MarginOperating income as percentage of revenue

9.46%

ROEReturn on shareholders' equity

-0.01%

ROAReturn on total assets

-0.00%

ROCEReturn on capital employed

3.19%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.002

Cash/ShareCash and equivalents per share

$0.40

FCF YieldFree cash flow as percentage of market cap

0.14%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for VBIZFFinancial Ratios Analysis details for VBIZF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for VBIZFSector Benchmarking details for VBIZF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Viva Biotech Holdings Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Viva Biotech Holdings. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Viva Biotech Holdings's unique business strengths and challenges.

Key Financial Metrics for Viva Biotech Holdings

For Viva Biotech Holdings, essential financial indicators include EPS 0.01, PE 18.90, and ROE -0.00. These key ratios reveal insights into Viva Biotech Holdings's profitability, valuation, and operational health. Understanding these metrics enables you to compare Viva Biotech Holdings with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Viva Biotech Holdings

Metrics like Net Margin -0.02% and ROA -0.00% shed light on how well Viva Biotech Holdings is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Viva Biotech Holdings can sustain its operations and continue growing in the future.

Valuation and Market Position of Viva Biotech Holdings

Using ratios such as P/B Ratio 0.83 and PEG Ratio -13.88, investors can assess whether Viva Biotech Holdings is appropriately valued based on its financials and growth potential. These figures, combined with Viva Biotech Holdings's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Viva Biotech Holdings

Financial health indicators, such as Debt/Equity Ratio 0.34 and Cash Flow $0.002, provide a snapshot of Viva Biotech Holdings's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Viva Biotech Holdings, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Viva Biotech Holdings

Investing in Viva Biotech Holdings based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Viva Biotech Holdings focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;